Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Response of AHU377 + Valsartan in Systolic Hypertension
NCT01281306Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2011
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of sacubitril in isolated systolic hypertension (ISH) (7 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Mean Sitting Systolic Blood Pressure at 8 weeks. Started Jan 2011; status: completed.
02
Drugs
sacubitril
03
Conditions
isolated systolic hypertension (ISH)
Beyond the preview
Go deeper on NCT01281306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01281306.